The Myeloproliferative Disorders
Top Cited Papers
- 7 December 2006
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (23) , 2452-2466
- https://doi.org/10.1056/nejmra063728
Abstract
The discovery of an identical mutation (V617F) of the JAK2 gene in patients with polycythemia vera, essential thrombocythemia, and myelofibrosis — the principal Philadelphia chromosome–negative myeloproliferative disorders — has greatly advanced our understanding of these conditions. This article reviews the legacy of this discovery and how it has changed our view of the origins, interrelations, and management of the myeloproliferative disorders.Keywords
This publication has 103 references indexed in Scilit:
- The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationProceedings of the National Academy of Sciences, 2006
- The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patientsBlood, 2005
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and StabilityJournal of Biological Chemistry, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genesOncogene, 2000
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000
- JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietinCell, 1993
- Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. KnochenmarksbefundVirchows Archiv, 1879